首站-论文投稿智能助手
典型文献
Infection and pathogenesis of the Delta variant of SARS-CoV-2 in Rhesus macaque
文献摘要:
Dear Editor, COVID-19 caused by SARS-CoV-2,is still a big threat to human populations around the world.As of Jan 2022,over 292 million cases were reported worldwide with more than 5.4 million deaths.
文献关键词:
作者姓名:
Ge Gao;Xue Hu;Yiwu Zhou;Juhong Rao;Xiaoyu Zhang;Yun Peng;Jiaxuan Zhao;Yanfeng Yao;Kunpeng Liu;Mengying Liang;Hang Liu;Fei Deng;Han Xia;Chao Shan;Zhiming Yuan
作者机构:
Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;Department of Forensic Medicine,Tongji Medical College of Huazhong University of Science and Technology,Wuhan,430030,China;University of Chinese Academy of Sciences,Beijing,100049,China;University of Chinese Academy of Sciences, Beijing, 100049, China;Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China;Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China
文献出处:
引用格式:
[1]Ge Gao;Xue Hu;Yiwu Zhou;Juhong Rao;Xiaoyu Zhang;Yun Peng;Jiaxuan Zhao;Yanfeng Yao;Kunpeng Liu;Mengying Liang;Hang Liu;Fei Deng;Han Xia;Chao Shan;Zhiming Yuan-.Infection and pathogenesis of the Delta variant of SARS-CoV-2 in Rhesus macaque)[J].中国病毒学,2022(02):299-302
A类:
Rhesus, COVID
B类:
Infection,pathogenesis,Delta,variant,SARS,CoV,macaque,Dear,Editor,caused,by,still,big,threat,human,populations,around,Jan,over,million,cases,were,reported,worldwide,more,than,deaths
AB值:
0.689878
相似文献
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
Yao Zhao;Chao Fang;Qi Zhang;Ruxue Zhang;Xiangbo Zhao;Yinkai Duan;Haofeng Wang;Yan Zhu;Lu Feng;Jinyi Zhao;Maolin Shao;Xiuna Yang;Leike Zhang;Chao Peng;Kailin Yang;Dawei Ma;Zihe Rao;Haitao Yang-Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology,ShanghaiTech University,Shanghai 201210,China;State Key Laboratory of Bioorganic&Natural Products Chemistry,Center for Excellence in Molecular Synthesis,Shanghai Institute of Organic Chemistry,University of Chinese Academy of Sciences,Chinese Academy of Sciences,Shanghai 200032,China;CAS Center for Excellence in Molecular Cell Science,Shanghai Institute of Biochemistry and Cell Biology,Chinese Academy of Sciences,Shanghai 200031,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China;National Facility for Protein Science in Shanghai,Zhangjiang Lab,Shanghai Advanced Research Institute,Chinese Academy of Sciences,Shanghai 201210,China;Taussig Cancer Center,Cleveland Clinic,Cleveland,OH 44195,USA;Laboratory of Structural Biology,School of Life Sciences and School of Medicine,Tsinghua University,Beijing 100091,China;State Key Laboratory of Medicinal Chemical Biology,Frontiers Science Center for Cell Response,College of Life Sciences,Nankai University,and Tianjin Key Laboratory of Protein Sciences,Tianjin 300071,China
Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
Yunlong Cao;Xiaohua Hao;Xi Wang;Qianhui Wu;Rui Song;Dong Zhao;Weiliang Song;Yao Wang;Ayijiang Yisimayi;Wei Wang;Wen Zhang;Juan Du;Hongjie Yu;Xiaoliang Sunney Xie;Ronghua Jin-Changping Laboratory,Beijing,China;Biomedical Pioneering Innovation Center (BIOPIC),Peking University,Beijing,China;Beijing Advanced Innovation Center for Genomics (ICG),Peking University,Beijing,China;National Center For Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing,China;Beijing Key Laboratory of Emerging Infectious Diseases,Institute of Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing,China;School of Public Health,Fudan University,Key Laboratory of Public Health Safety,Ministry of Education,Shanghai,China;School of Life Sciences,Peking University,Beijing,China;Shanghai Institute of Infectious Disease and Biosecurity,Fudan University,Shanghai,China;Department of Infectious Diseases,Huashan Hospital,Fudan University,Shanghai,China
Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Na-Na Zhang;Rong-Rong Zhang;Yi-Fei Zhang;Kai Ji;Xiao-Chuan Xiong;Qian-Shan Qin;Peng Gao;Xi-Shan Lu;Hang-Yu Zhou;Hai-Feng Song;Bo Ying;Cheng-Feng Qin-Department of Virology,State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd.,Suzhou,Jiangsu,China;School of Life Sciences,Fujian Agriculture and Forestry University,Fuzhou,Fujian,China;Institute of Systems Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
Shuai Xia;Jasper Fuk-Woo Chan;Lijue Wang;Fanke Jiao;Kenn Ka-Heng Chik;Hin Chu;Qiaoshuai Lan;Wei Xu;Qian Wang;Chao Wang;Kwok-Yung Yuenuai;Lu Lu;Shibo Jiang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Shanghai Institute of Infectious Disease and Biosecurity,Fudan University,Shanghai,China;State Key Laboratory of Emerging Infectious Diseases,Carol Yu Centre for Infection,Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;Department of Clinical Microbiology and Infection Control,The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,China;Centre for Virology,Vaccinology and Therapeutics,Hong Kong Science and Technology Park,Hong Kong,China;State Key Laboratory of Toxicology and Medical Countermeasures,Beijing Institute of Pharmacoloay and Toxicoloay,Beijing,China
Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209
Bin Ju;Qingbing Zheng;Huimin Guo;Qing Fan;Tingting Li;Shuo Song;Hui Sun;Senlin Shen;Xinrong Zhou;Wenhui Xue;Lingyan Cui;Bing Zhou;Shaowei Li;Ningshao Xia;Zheng Zhang-Institute for Hepatology,National Clinical Research Center for Infectious Disease,Shenzhen Third People's Hospital;The Second Affiliated Hospital,School of Medicine,Southern University of Science and Technology,Shenzhen,Guangdong,China;Guangdong Key laboratory for anti-infection Drug Quality Evaluation,Shenzhen,Guangdong,China;State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,School of Life Sciences,School of Public Health,Xiamen University,Xiamen,Fujian,China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases,Xiamen University,Xiamen,Fujian,China;Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science,Shenzhen,Guangdong,China
A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant
Zezhong Liu;Jasper Fuk-Woo Chan;Jie Zhou;Meiyu Wang;Qian Wang;Guangxu Zhang;Wei Xu;Kenn Ka-Heng Chik;Yilong Zhang;Youchun Wang;Kwok-Yung Yuen;Lu Lu;Shibo Jiang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Shanghai Institute of Infectious Disease and Biosecurity,Fudan University,Shanghai,China;State Key Laboratory of Emerging Infectious Diseases,Carol Yu Centre for Infection,Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;Department of Clinical Microbiology and Infection Control,The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,China;Centre for Virology,Vaccinology and Therapeutics,Hong Kong Science and Technology Park,Hong Kong,China;Graduate School of Peking Union Medical College,Beijing,China;Division of HIV/AIDS and Sex-transmitted Virus Vaccines,Institute for Biological Product Control,National Institutes for Food and Drug Control(NIFDC),Beijing,China;Fulgent Pharma LLC.,4978 Santa Anita Avenue,Temple City,CA,USA
Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang-Fudan University,Shanghai,China;Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China;Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Emerging Infectious Diseases,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin,China;CenBRAIN Lab.,School of Engineering,Westlake University,Hangzhou,Zhejiang,China;CenBRAIN Lab.,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China
Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
Jun Lan;Xinheng He;Yifei Ren;Ziyi Wang;Huan Zhou;Shilong Fan;Chenyou Zhu;Dongsheng Liu;Bin Shao;Tie-Yan Liu;Qisheng Wang;Linqi Zhang;Jiwan Ge;Tong Wang;Xinquan Wang-The Ministry of Education Key Laboratory of Protein Science,Beijing Advanced Innovation Center for Structural Biology,Beijing Frontier Research Center for Biological Structure,Collaborative Innovation Center for Biotherapy,School of Life Sciences,Tsinghua University,Beijing,China;Microsoft Research Asia,Beijing,China;Shanghai Synchrotron Radiation Facility,Shanghai Advanced Research Institute,Chinese Academy of Sciences,Shanghai,China;Department of Chemistry,Tsinghua University,Beijing,China;Center for Global Health and Infectious Diseases,Comprehensive AIDS Research Center,and Beijing Advanced Innovation Center for Structural Biology,School of Medicine,Tsinghua University,Beijing,China
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu;Yuhua Li;Zhongfang Wang;Shouchun Cao;Weijin Huang;Lin Yuan;Yi-Jiao Huang;Yan Zheng;Jingjing Chen;Bo Ying;Zuoyun Xiang;Jin Shi;Jincun Zhao;Zhen Huang;Cheng-Feng Qin-Yunnan Province Centre for Disease Control and Prevention,Kunming,Yunnan,China;National Institutes for Food and Drug Control,Beijing,China;Respiratory Medicine,Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong,China;Walvax Biotechnology Co.,Ltd.,Kunming,Yunnan,China;State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin,China:a retrospective study
Hong Zheng;Yunlong Cao;Xiaosu Chen;Fengmei Wang;Ye Hu;Weiliang Song;Yangyang Chai;Qingqing Gu;Yansong Shi;Yingmei Feng;Shuxun Liu;Yan Xie;Xiaoliang Sunney Xie;Wentao Jiang;Zhongyang Shen-Organ Transplant Center,NHC Key Laboratory for Critical Care Medicine,Tianjin First Central Hospital,Nankai University,Tianjin,China;Changping Laborarty,Beijing,China;Biomedical Pioneering Innovation Center(BIOPIC),Peking University,Beijing,China;Frontier Research Center for Cell Response,Institute of Immunology,College of Life Sciences,Nankai University,Tianjin,China;Institute of Hepatobiliary Disease,Tianjin Third Central Hospital,Tianjin,China;Department of Immunology,Center for Immunotherapy,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences,Beijing,China;Beijing Youan Hospital,Capital Medical University,Beijing,China;National Key Laboratory of Medical Immunology,Institute of Immunology,Navy Medical University,Shanghai,China
A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
Yingdan Wang;Wuqiang Zhan;Jiangyan Liu;Yanqun Wang;Xiang Zhang;Meng Zhang;Lin Han;Yunping Ma;Lu Lu;Yumei Wen;Zhenguo Chen;Jincun Zhao;Fan Wu;Lei Sun;Jinghe Huang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)and Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Fifth People's Hospital,Shanghai Public Health Clinical Center,Institutes of Biomedical Sciences,School of Basic Medical Sciences,Fudan University,Shanghai,China;Shanghai Immune Therapy Institute,Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital,Shanghai,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China
Omicron-specific mRNA vaccine elicits potent immune responses in mice,hamsters,and nonhuman primates
Yi Wu;Yanqiong Shen;Namei Wu;Xinghai Zhang;Shaohong Chen;Chang Yang;Junhui Zhou;Yan Wu;Da Chen;Li Wang;Chao Wang;Huajun Zhang;Ninuo Xia;Sandra Chiu;Yucai Wang-Department of Radiology,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;School of Basic Medical Sciences,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,Hubei,China;University of Chinese Academy of Sciences,Beijing,China;MOE Key Laboratory for Cellular Dynamics,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;RNAIfa Biotech,Hefei,Anhui,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。